Literature DB >> 19333071

MET pathway as a therapeutic target.

Eric S Kim1, Ravi Salgia.   

Abstract

Dysregulation of mesenchymal-epithelial transition factor receptor tyrosine kinase pathway leads to cell proliferation, protection from apoptosis, angiogenesis, invasion, and metastasis. It can be dysregulated through overexpression, constitutive activation, gene amplification, ligand-dependent activation or mutation. New drugs targeting various mesenchymal-epithelial transition factor pathways are being investigated with promising results.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19333071      PMCID： PMC2664527          DOI： 10.1097/JTO.0b013e31819d6f91

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


  50 in total

1.  The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3' kinase.

Authors:  S Fan; Y X Ma; J A Wang; R Q Yuan; Q Meng; Y Cao; J J Laterra; I D Goldberg; E M Rosen
Journal:  Oncogene       Date:  2000-04-27       Impact factor: 9.867

2.  A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein.

Authors:  L Lamorte; D M Kamikura; M Park
Journal:  Oncogene       Date:  2000-12-07       Impact factor: 9.867

Review 3.  Met, metastasis, motility and more.

Authors:  Carmen Birchmeier; Walter Birchmeier; Ermanno Gherardi; George F Vande Woude
Journal:  Nat Rev Mol Cell Biol       Date:  2003-12       Impact factor: 94.444

4.  HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.

Authors:  K Kuba; K Matsumoto; K Date; H Shimura; M Tanaka; T Nakamura
Journal:  Cancer Res       Date:  2000-12-01       Impact factor: 12.701

5.  Assessment of differential expression of oncogenes in gastric adenocarcinoma by fluorescent multiplex RT-PCR assay.

Authors:  U Rajcevic; R Juvan; B Gazvoda; S Repse; R Komel
Journal:  Pflugers Arch       Date:  2001       Impact factor: 3.657

6.  Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.

Authors:  Gautam Maulik; Takashi Kijima; Patrick C Ma; Sudip K Ghosh; Jeffrey Lin; Geoffrey I Shapiro; Erik Schaefer; Elena Tibaldi; Bruce E Johnson; Ravi Salgia
Journal:  Clin Cancer Res       Date:  2002-02       Impact factor: 12.531

7.  Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation.

Authors:  Yu-Wen Zhang; Yanli Su; Olga V Volpert; George F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-10       Impact factor: 11.205

8.  The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variants.

Authors:  Sylvie Berthou; Daniel M Aebersold; Laura S Schmidt; Deborah Stroka; Christine Heigl; Bruno Streit; Denise Stalder; Guenther Gruber; Congxin Liang; Anthony R Howlett; Daniel Candinas; Richard H Greiner; Kenneth E Lipson; Yitzhak Zimmer
Journal:  Oncogene       Date:  2004-07-08       Impact factor: 9.867

9.  K252a inhibits the oncogenic properties of Met, the HGF receptor.

Authors:  Alessandro Morotti; Silvia Mila; Paolo Accornero; Emma Tagliabue; Carola Ponzetto
Journal:  Oncogene       Date:  2002-07-25       Impact factor: 9.867

10.  Essential role of Gab1 for signaling by the c-Met receptor in vivo.

Authors:  M Sachs; H Brohmann; D Zechner; T Müller; J Hülsken; I Walther; U Schaeper; C Birchmeier; W Birchmeier
Journal:  J Cell Biol       Date:  2000-09-18       Impact factor: 10.539
View more
  26 in total

Review 1.  Role of MetMAb (OA-5D5) in c-MET active lung malignancies.

Authors:  Mosmi Surati; Premal Patel; Amy Peterson; Ravi Salgia
Journal:  Expert Opin Biol Ther       Date:  2011-12       Impact factor: 4.388

Review 2.  Targeting the HGF/Met signaling pathway in cancer therapy.

Authors:  Fabiola Cecchi; Danie C Rabe; Donald P Bottaro
Journal:  Expert Opin Ther Targets       Date:  2012-04-25       Impact factor: 6.902

3.  Expression patterns of PAX5, c-Met, and paxillin in neuroendocrine tumors of the lung.

Authors:  Jie Song; Mei Li; Maria Tretiakova; Ravi Salgia; Philip T Cagle; Aliya N Husain
Journal:  Arch Pathol Lab Med       Date:  2010-11       Impact factor: 5.534

4.  Genomic abnormalities in invasive endocervical adenocarcinoma correlate with pattern of invasion: biologic and clinical implications.

Authors:  Anjelica Hodgson; Yutaka Amemiya; Arun Seth; Matthew Cesari; Bojana Djordjevic; Carlos Parra-Herran
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

5.  A comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.

Authors:  Aung Naing; Razelle Kurzrock; Laurel M Adams; Joseph F Kleha; Kevin H Laubscher; Peter L Bonate; Steven Weller; Colleen Fitzgerald; Yanmei Xu; Patricia M LoRusso
Journal:  Invest New Drugs       Date:  2010-09-15       Impact factor: 3.850

6.  Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.

Authors:  Cleo E Rolle; Rajani Kanteti; Mosmi Surati; Suvobroto Nandi; Immanuel Dhanasingh; Soheil Yala; Maria Tretiakova; Qudsia Arif; Todd Hembrough; Toni M Brand; Deric L Wheeler; Aliya N Husain; Everett E Vokes; Ajit Bharti; Ravi Salgia
Journal:  Mol Cancer Ther       Date:  2013-12-10       Impact factor: 6.261

Review 7.  Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma.

Authors:  Andres Morales La Madrid; Andres Morales La Madrid; Nicholas Campbell; Sonali Smith; Susan L Cohn; Ravi Salgia
Journal:  Target Oncol       Date:  2012-09-12       Impact factor: 4.493

8.  Distinct MHC gene expression patterns during progression of melanoma.

Authors:  Yan Degenhardt; Jia Huang; Joel Greshock; Galene Horiates; Katherine Nathanson; Xiaolu Yang; Meenhard Herlyn; Barbara Weber
Journal:  Genes Chromosomes Cancer       Date:  2010-02       Impact factor: 5.006

9.  Molecularly targeted therapies for advanced or metastatic non-small-cell lung carcinoma.

Authors:  Soley Bayraktar; Caio M Rocha-Lima
Journal:  World J Clin Oncol       Date:  2013-05-10

10.  MET/PKCbeta expression correlate with metastasis and inhibition is synergistic in lung cancer.

Authors:  Leonardo Faoro; Gustavo M Cervantes; Benjamin D Ferguson; Tanguy Y Seiwert; Soheil Yala; Wicki T Vigneswaran; Maria Westerhoff; Maria S Tretiakova; Mark K Ferguson; Glaci L Moura; Aliya N Husain; Everett E Vokes; Ravi Salgia
Journal:  J Carcinog       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.